Treatment of depression in Huntington's disease with monoamine oxidase inhibitors.
Depression is common in Huntington's disease. It is customary to treat such patients with tricyclic antidepressants, although there is disagreement about their effectiveness. The use of monomine oxidase inhibitors for depression in HD has not previously been reported; three cases are described here. MAOIs appear to be of value in the management of depression in HD.
D000328:Adult; D000368:Aged; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000150:complications*; D007520:Isocarboxazid / Q000627:therapeutic use; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010624:Phenelzine / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D007520:Isocarboxazid; D010624:Phenelzine